Elie G. Dib: Excited to share the results of the TAPUR study
Elie G. Dib, Associate Director of the Haematology-Oncology Training Program at Saint Joseph Mercy Hospital, posted on LinkedIn:
“Excited to share the results of the TAPUR study on the use of pertuzumab plus trastuzumab in patients with biliary tract cancer and ERBB2/3 alterations!
This regimen demonstrated meaningful clinical activity in this difficult-to-treat population across multiple institutions. The advances in targeted therapy and precision medicine continue to drive progress for patients with biliary tract cancers. Trinity Health is proud to be part of this important national research effort.
A big thank you to my co-authors, the research team, and most importantly, the patients who participated. This is an encouraging step forward.”
Proceed to the article.
Source: Elie G. Dib/LinkedIn